{"id":35049,"date":"2025-06-11T15:35:31","date_gmt":"2025-06-11T07:35:31","guid":{"rendered":"https:\/\/flcube.com\/?p=35049"},"modified":"2025-06-11T15:35:32","modified_gmt":"2025-06-11T07:35:32","slug":"mercks-pimicotinib-nda-accepted-for-review-by-chinas-cde","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35049","title":{"rendered":"Merck’s Pimicotinib NDA Accepted for Review by China’s CDE"},"content":{"rendered":"\n

German pharmaceutical major Merck KGaA (ETR: MRK<\/a>) announced that the New Drug Application (NDA) for pimicotinib has been accepted for review by China’s Center for Drug Evaluation (CDE). The drug is indicated for adult patients with tenosynovial giant cell tumor (TGCT) requiring systemic therapy. Pimicotinib previously received Priority Review and Breakthrough Therapy designations from the CDE.<\/p>\n\n\n\n

Clinical Trial Results<\/strong>
The NDA submission is based on the global Phase III MANEUVER study, which achieved its primary endpoint. At week 25, the objective response rate (ORR) in the pimicotinib group was 54.0%, significantly higher than the placebo group’s 3.2%. Pimicotinib demonstrated statistically and clinically significant improvements in key secondary endpoints related to patient-reported outcomes (PRO), including enhanced range of motion, physical function, and reduced stiffness and pain.<\/p>\n\n\n\n

Global Licensing Agreement<\/strong>
Pimicotinib is a potentially best-in-class CSF-1R inhibitor developed by Abbisko Therapeutics (HKG: 2256<\/a>). Merck initially entered a USD 600 million licensing agreement with Abbisko in December 2023 for commercial rights in Mainland China, Hong Kong, Macau, and Taiwan. In April this year, Merck exercised an option to obtain worldwide commercialization rights for pimicotinib.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

German pharmaceutical major Merck KGaA (ETR: MRK) announced that the New Drug Application (NDA) for…<\/p>\n","protected":false},"author":1,"featured_media":35051,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[186,1147,38,120,25],"class_list":["post-35049","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-abbisko-therapeutics","tag-etr-mrk","tag-market-approval-filings","tag-merck","tag-potential-first-in-class"],"yoast_head":"\nMerck's Pimicotinib NDA Accepted for Review by China's CDE - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"German pharmaceutical major Merck KGaA (ETR: MRK) announced that the New Drug Application (NDA) for pimicotinib has been accepted for review by China's Center for Drug Evaluation (CDE). The drug is indicated for adult patients with tenosynovial giant cell tumor (TGCT) requiring systemic therapy. Pimicotinib previously received Priority Review and Breakthrough Therapy designations from the CDE.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35049\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck's Pimicotinib NDA Accepted for Review by China's CDE\" \/>\n<meta property=\"og:description\" content=\"German pharmaceutical major Merck KGaA (ETR: MRK) announced that the New Drug Application (NDA) for pimicotinib has been accepted for review by China's Center for Drug Evaluation (CDE). The drug is indicated for adult patients with tenosynovial giant cell tumor (TGCT) requiring systemic therapy. Pimicotinib previously received Priority Review and Breakthrough Therapy designations from the CDE.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35049\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-11T07:35:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-11T07:35:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1108.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35049#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35049\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Merck’s Pimicotinib NDA Accepted for Review by China’s CDE\",\"datePublished\":\"2025-06-11T07:35:31+00:00\",\"dateModified\":\"2025-06-11T07:35:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35049\"},\"wordCount\":193,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35049#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1108.webp\",\"keywords\":[\"Abbisko Therapeutics\",\"ETR: MRK\",\"Market approval filings\",\"Merck\",\"Potential first-in-class\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35049#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35049\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35049\",\"name\":\"Merck's Pimicotinib NDA Accepted for Review by China's CDE - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35049#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35049#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1108.webp\",\"datePublished\":\"2025-06-11T07:35:31+00:00\",\"dateModified\":\"2025-06-11T07:35:32+00:00\",\"description\":\"German pharmaceutical major Merck KGaA (ETR: MRK) announced that the New Drug Application (NDA) for pimicotinib has been accepted for review by China's Center for Drug Evaluation (CDE). The drug is indicated for adult patients with tenosynovial giant cell tumor (TGCT) requiring systemic therapy. Pimicotinib previously received Priority Review and Breakthrough Therapy designations from the CDE.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35049#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35049\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35049#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1108.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1108.webp\",\"width\":1080,\"height\":608,\"caption\":\"Merck's Pimicotinib NDA Accepted for Review by China's CDE\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35049#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck’s Pimicotinib NDA Accepted for Review by China’s CDE\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck's Pimicotinib NDA Accepted for Review by China's CDE - Insight, China's Pharmaceutical Industry","description":"German pharmaceutical major Merck KGaA (ETR: MRK) announced that the New Drug Application (NDA) for pimicotinib has been accepted for review by China's Center for Drug Evaluation (CDE). The drug is indicated for adult patients with tenosynovial giant cell tumor (TGCT) requiring systemic therapy. Pimicotinib previously received Priority Review and Breakthrough Therapy designations from the CDE.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35049","og_locale":"en_US","og_type":"article","og_title":"Merck's Pimicotinib NDA Accepted for Review by China's CDE","og_description":"German pharmaceutical major Merck KGaA (ETR: MRK) announced that the New Drug Application (NDA) for pimicotinib has been accepted for review by China's Center for Drug Evaluation (CDE). The drug is indicated for adult patients with tenosynovial giant cell tumor (TGCT) requiring systemic therapy. Pimicotinib previously received Priority Review and Breakthrough Therapy designations from the CDE.","og_url":"https:\/\/flcube.com\/?p=35049","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-11T07:35:31+00:00","article_modified_time":"2025-06-11T07:35:32+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1108.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35049#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35049"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Merck’s Pimicotinib NDA Accepted for Review by China’s CDE","datePublished":"2025-06-11T07:35:31+00:00","dateModified":"2025-06-11T07:35:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35049"},"wordCount":193,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35049#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1108.webp","keywords":["Abbisko Therapeutics","ETR: MRK","Market approval filings","Merck","Potential first-in-class"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35049#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35049","url":"https:\/\/flcube.com\/?p=35049","name":"Merck's Pimicotinib NDA Accepted for Review by China's CDE - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35049#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35049#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1108.webp","datePublished":"2025-06-11T07:35:31+00:00","dateModified":"2025-06-11T07:35:32+00:00","description":"German pharmaceutical major Merck KGaA (ETR: MRK) announced that the New Drug Application (NDA) for pimicotinib has been accepted for review by China's Center for Drug Evaluation (CDE). The drug is indicated for adult patients with tenosynovial giant cell tumor (TGCT) requiring systemic therapy. Pimicotinib previously received Priority Review and Breakthrough Therapy designations from the CDE.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35049#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35049"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35049#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1108.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1108.webp","width":1080,"height":608,"caption":"Merck's Pimicotinib NDA Accepted for Review by China's CDE"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35049#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Merck’s Pimicotinib NDA Accepted for Review by China’s CDE"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1108.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35049","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35049"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35049\/revisions"}],"predecessor-version":[{"id":35052,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35049\/revisions\/35052"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35051"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35049"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35049"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35049"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}